OBJECTIVE： To compare the efficacy and safety of ferrous succinate or Shengxuening in the adjuvant treatment of renal anemia in patients with diabetic nephropathy peritoneal dialysis （CAPD）. METHODS： 64 diatetic nephropathy  CAPD patients with renal anemia were randomly divided into observation group （32 cases） and control group （32 cases）. All patients received subcutaneous injection of insulin for blood glucose control （adjusted the insulin dosage based on fasting blood glucose levels），hypertension patients actively controlled blood pressure，corrected acid-base and electrolyte balance disorders，orally received folic acid and vitamin B12，ambulant CAPD，then rhEPO was subcutaneously injected with initial dose of 100-150 U/（kg·week） for 2-3 times and other conventional treatment. Based on it， observation group received 1 g of Shengxuening tablet， 3 times a day； control group received 0.2 g Ferrous succinate tablet， 3 times a day. The treatment course for both groups was 16 weeks. The rhEPO dose was monthly adjusted to make Hb 100-120 g/L. Clinical efficacy， serum iron， serum ferritin， total iron binding capacity， transferrin saturation before and after treatment， Hb， Hct， hs-CRP， rhEPO dose before treatment and after 4， 8， 12 and 16 weeks of treatment， and the incidence of adverse reactions in 2 groups were observed. RESULTS： There was no significant difference in the total effective rate between 2 groups （P＞0.05）. After treatment， serumiron，total iron binding capacity，transferrin saturation， Hb and Hct in 2 groups were significantly higher than before， and it gradually increased by treatment time， serum ferritin， hs-CRP was significantly lower than before， and it gradually decreased by treatment time， the differences were statistically significant （P＜0.05）； but there was no significant difference between 2 groups （P＞0.05）. The rhRPO dose in observation group 8， 16 and 16 weeks after treatment and in control group 8 weeks after treatment were significantly lower than 4 weeks after treatment， and 12 and 16 weeks after treatment in observation group were lower than control group， the differences were statistically significant （P＜0.05）. The incidence of adverse reactions in observation group was significantly lower than control group， the difference was statistically significant （P＜0.05）. CONCLUSIONS： Based on conventional treatment， both ferrous succinate and Shengxuening show good efficacy in the adjuvant treatment of renal anemia with diabetic nephropathy CAPD， both can improve anemia and iron metabolism， while Shengxuening is superior to ferrous succinate in terms of improving microinflammatory state and reducing rhEPO dose， with better safety.